In an effort to reduce the relapse rate after unpurged autologous bone marrow transplantation (ABMT) in patients with acute myeloid leukemia (AML) in first complete remission (CR1), the standard conditioning regimens (cyclophosphamide/busulphan and cyclophosphamide/TBI) were intensified by adding idarubicin. Seventeen patients received a continuous infusion of 21 mg idarubicin/m 2 /day for 2 consecutive days in addition to the standard preparative regimen. Thirteen patients served as a historical control group. The 2-year disease-free survival (DFS) of 82% in the study group was significantly (P = 0.047) better compared to 46% DFS in the control group. The relapse rate (RR) was also significantly lower (7% vs 45%; P = 0.035) in the study group. The median time to reach a white cell count (WCC) of 0.5 × 10 9 /l was 20 days in the study group vs 17 days (P = NS) in the control group. The median time until recovery of the platelet counts to 20 × 10 9 /l was 152 days in the study group vs 57 days (P = NS) in the control group. The hypolasia in the study group resulted in a trend towards a higher need for transfusions: a median number of 38 units of erythrocytes vs 23 units in the control group (P = NS) and 23 units of platelet vs 18 units in the control group (P = NS). This pilot study suggests that addition of idarubicin to the standard conditioning regimens may improve DFS and overall survival (OS) of patients with AML treated with ABMT in CR1. These results should be confirmed in a prospective randomized study. Keywords: idarubicin; conditioning regimens; autologous bone marrow transplantation; acute myeloid leukemia; first complete remission A complete remission (CR) rate of 70-80% can be achieved in patients with newly diagnosed acute myeloid leukemia (AML) by currently used remission-induction regimens. Addition of a third drug such as etoposide, 1,2 replacement of daunorubicin by new anthracyclines such as idarubicin, [3] [4] [5] Correspondence: Dr Sh Jerjis, Division of Hematology, University Hospital St Radboud, Geert Grooteplein Zuid 8, 6525 GA Nijmegen, The Netherlands Received 24 October 1997; accepted 14 February 1998 and high-dose cytarabine (HiDAC) 6,7 have improved the remission percentage of conventional regimens based on 3 days of daunorubicin and 10 days of standard-dose cytarabine. 8 Without further treatment almost all patients are expected to relapse. Only 10-15% of patients will be cured by using standard-dose consolidation and maintenance therapy. A higher DFS of 25-45% may be achieved after intensive consolidation chemotherapy.
and high-dose cytarabine (HiDAC) 6, 7 have improved the remission percentage of conventional regimens based on 3 days of daunorubicin and 10 days of standard-dose cytarabine. 8 Without further treatment almost all patients are expected to relapse. Only 10-15% of patients will be cured by using standard-dose consolidation and maintenance therapy. A higher DFS of 25-45% may be achieved after intensive consolidation chemotherapy. 9, 10 Allogeneic BMT as well as ABMT in de novo AML patients when performed during CR1 results in better DFS than intensive consolidation therapy [11] [12] [13] and greater antileukemic activity when performed in CR2. 14, 15 Relapse is the main cause of death in hematologic malignancies after BMT, and even more so after ABMT. Combining the standard conditioning regimens (cyclophosphamide/busulphan and cyclophosphamide/TBI) with non-cross-resistant agents and selecting agents without overlapping toxicity may improve its efficacy. In this study we evaluated the antileukemic activity and the toxicity of the two standard conditioning regimens after intensification by the addition of a continuous infusion of idarubicin. Regimens intensified with idarubicin have shown promising results in the allogeneic transplant setting. [16] [17] [18] [19] [20] 
Patients and methods

Diagnosis and treatment of acute myeloid leukemia
Diagnosis of AML was based on the FAB classification criteria using standard morphology and cytochemistry. In addition, at least 32 marrow metaphases were analyzed by standard cytogenetic banding techniques from bone marrow obtained before initiation of treatment. Patients were considered in morphologic CR when the bone marrow contained less than 5% blasts and the blood counts had recovered to normal values, and in cytogenetic remission when the cytogenetic abnormality disappeared. Relapse was diagnosed when the bone marrow contained more than 5% blasts. Cytogenetic relapse was diagnosed when the original cytogenetic abnormalities had re-emerged.
Bone marrow was harvested after completion of one or two consolidation courses. For a successful repopulation after transplantation at least 2 × 10 6 CD34 cells/kg body weight (b.w.) and/or 20 × 10 4 CFU-GM/kg b.w. were collected. No marrow purging was attempted. Marrow cells were processed, cryopreserved, and thawed as described before. 21 No growth factors were administered after ABMT. Informed consent was obtained according to the rules of Dutch law.
Patients
Thirty consecutive patients who had been treated by ABMT for AML in CR1 between August 1984 and August 1996 in the Nijmegen University Hospital were included in this evaluation. As a historical control group 13 patients were treated with the standard regimens and 17 with the intensified regimens. The patients were treated with remission induction and consolidation courses according to the current European Organization for Research and Treatment of Cancer protocols (EORTC-LCG AML-6, 22 EORTC-LCG AML-8 23 and EORTC-LCG/GIMEMA AML-10 24 ), only three patients who had been referred from abroad were given remission induction and consolidation courses according to the TAD regimen (thioguanine, cytarabine and daunomycin). 25 Six of these patients participated in a prospective, placebo-controlled study with linomide 26 after ABMT. Three patients received placebo and three patients linomide. Since the number of patients was small we did not analyze the influence of linomide on the outcome of the patients in this analysis. Patient characteristics are detailed in Table 1 . The median age of the patients in the control group was 38 years (range 20-60), while in the study group it was 43 years (range 29-58).
Four patients were classified as M1, 14 as M2, one as M3, eight as M4, one as M5, and two as M6. Patients were subdivided into bad prognostic (M4 and M5) and good prognostic (others) subtypes, and the difference in distribution between these subtypes was not significant. Patients were also subdivided into cytogenetic risk groups according to Keating et al. 27 No significant difference was observed between the two groups ( Table 1) . Four patients (24%) in the study group had leukocyte counts above 30 × 10 9 /l at diagnosis, compared to eight patients (62%) in the control group (P = 0.03). The median number of infused CFU-GM/kg b.w. was similar in both groups (Table 2 ). Four patients in the control group (31%) received two remissioninduction courses to achieve CR1 compared to three patients (18%) in the study group (Table 1) . Two patients in the control and one in the study group received two consolidation courses prior to the marrow harvest. The interval between CR1 and ABMT was not significantly different between the two groups ( Table 2) .
Conditioning regimens
Two types of standard conditioning regimens were used in this study. The first regimen (Bu/Cy) consisted of oral busulphan 4 × 1 mg/kg b.w. daily for 4 days from day −8 until day −5, followed by intravenous cyclophosphamide 60 mg/kg b.w. daily on days −3 and −2. To prevent seizures phenytoin was administered orally at a dose of 100 mg three times daily from 24 h before the first dose of busulphan until 24 h after the last dose. To prevent veno-occlusive disease intravenous heparin was administered at a dose of 100 U/kg b.w. until day +14. The second regimen (Cy/TBI) consisted of intravenous cyclophosphamide 60 mg/kg b.w., daily on days −7 and −6 followed by total body irradiation 4.5 Gy per day on days −2 and −1. Several prophylactic procedures were used to prevent hemorrhagic cystitis after cyclophosphamide infusion. Hyperhydration started 20 h before infusion of cyclophosphamide, with 3 l/day until 4 days after completion of the cyclophosphamide infusion. This was combined with alkalinization of urine by 1000 ml NaHCO 3 (4.2%) per day and infusion of intravenous mesna 20 mg/kg b.w. in 10 ml NaCl 0.9% during the cyclophosphamide infusion and 3, 6 and 9 h thereafter.
Fifteen patients were treated with the Bu/Cy regimen: six patients in the control group and nine in the study group. Fifteen patients received the Cy/TBI regimen: seven in the control group and eight in the study group (Table 1) . The standard preparative regimens were intensified by a con- In an earlier study 16 the cardiac ejection fraction was measured by a nuclear (isotope) method before and after anthracycline administration and this has not changed. For this study an ejection fraction was measured only when indicated (age above 60 years, excessive anthracycline administration or cardiac symptoms). A value below 50% was a contraindication for idarubicin administration.
Suportive care
All transfused blood products were depleted of leukocytes in order to minimize the risk of alloimmunization. They were also irradiated to prevent graft-versus-host disease. Oral infection prophylaxis consisted of ciprofloxacin 2 × 500 mg per day, cotrimoxazole 2 × 960 mg per day twice weekly, acyclovir 4 × 400 mg per day, amphotericin B lozenges 4 × 400 mg per day and amphotericin inhalations 2 × 10 mg per day. This prophylaxis was given until the leukocyte counts had reached 1 × 10 9 /l. Cotrimoxazole was continued until 6 months after hospitalization. The number of days with fever of more than 38.5°C and the number of days of four main groups of medication were analyzed: antibiotics, antifungals, antivirals and morphine. During admission, blood, stool, and pharyngeal cultures were routinely taken twice weekly. Indications for intravenous antibiotics were as follows: fever 38.5°C with leukocyte counts less than 1 × 10 9 /l, positive blood cultures, and positive stool cultures or cultures from pharynx with signs or symptoms of infection. Intravenous acyclovir 3 × 500 mg daily was administered after diagnosis of herpes simplex. Intravenous fluconazol was used for proven candidiasis infections. Intravenous amphotericin B or oral itraconazol were used in suspected or proven aspergillosis. Painful oromucositis was treated with continuous intravenous infusion of morphine.
Statistics
Disease-free survival was defined as the time from ABMT until the day of relapse, death or the date of analysis, 17 October 1997. Overall survival was defined as the time from ABMT until death or the date of analysis. Death before repopulation was considered treatment-related mortality whatever the cause of the death. Death after relapse was considered to be due to leukemia. Disease-free survival, OS and RR were evaluated by the Kaplan-Meier method. Differences between the curves were tested for statistical significance by the log-rank test. Categorical data were compared by the 2 test and continuous data by the Mann-Whitney U test.
Results
Hematopoietic recovery
In the study group, two patients died 37 and 208 days after ABMT with leukocyte and platelet counts below 0.5 × 10 /l were 152 and 251, respectively, in the study group, compared to 57 (P = NS) and 183 in the control group.
The median interval from ABMT until the last platelet and erythrocyte transfusion in the study group was 72 days (range 13-1025) and 159 days (range 12-1025) respectively, compared to 45 days (range 23-167; P = NS) and 152 days (range 42-344; P = NS) in the control group (Table 3) .
Toxicity and hospitalization duration
Two of 13 patients in the control group died 38 and 22 days after transplantation without repopulation, from pneumonia with bacteremia and veno-occlusive disease, respectively. Two of 17 patients in the intensified group died from hemorrhage and pulmonary aspergillosis 37 and 208 days after transplantation, respectively. Cardiotoxic complications were not observed in the patients of the two groups. Table 3 The median number of days of hospitalization and repopulation of leukocytes and platelets, and the median number of blood transfusions The TRM was 12% in the study group compared to 15% in the control group. The number of days with fever more than 38.5°C and intravenous antimicrobial agents was calculated as an estimate of serious infections in both groups (Table 4 ). The mean number of days on intravenous antibiotics was 29 in the group with intensified regimens vs 15 (P = 0.02) in the control group. Patients conditioned with the intensified regimens received intravenous antifungal drugs (amphotericin B and fluconazol) for more days (12 days) than in the control group (2 days) (P = 0.05). Intravenous acyclovir was administered for 5 and 6 days (P = NS) in the intensified and control group, respectively. The mean number of days of fever higher than 38.5°C in the study group was 14.8, vs 7.2 in the control group (P = 0.006). Intravenous narcotic analgesics were routinely prescribed to treat pain due to severe oromucositis. The mean amount of morphine was significantly higher (P = 0.04) in the study group (Table 4) . Seven patients (41%) developed bleeding in the study group: three hematuria one of them with thrombosis; two hematoma one of them with petechia and the other with hemoptysis, one epistaxis and one vaginal bleeding. Only two patients (15%) developed gastrointestinal bleeding in the control group (P = NS). Twelve patients (71%) on intensified regimens showed positive bacterial blood cultures, eight with staph epidermidis. Six patients in the historical group developed positive bacterial blood cultures, five due to strep mitis, and one patient (54%) had a blood culture positive for candidiasis (P = NS). In the study group one patient developed bilateral pulmonary infiltrates. A second one showed a unilateral infiltration and the third patient developed unilateral sinus infiltration. Only one patient developed unilateral pulmonary infiltration in the control group. Nine patients (53%) in the study group showed clinical features of mucositis in comparison to three (23%) in the control group (P = NS). The mean number of hospitalization days in the study group was 42 (range 28-97), compared to 39 (range in the control group (P = NS) ( Table 3 ).
Control
Outcome
Six of 13 patients in the control group survive without cytogenetic or morphological evidence of relapse between 3.8 and 9.8 years after transplantation (median 6.8 years). In Table 4 The mean duration of administration of intravenous antimicrobial agents, morphine and days with fever more than 38.5°C contrast, 13 of 17 patients in the study group survive without relapse between 1.04 and 5.15 years (median 3.1 years). The 2-year DFS and OS for all patients in the two groups of the study estimated by Kaplan-Meier analysis were 66% (95% confidence interval (CI) = 49-83%). The 2-year DFS (Figure 1 ) in the group prepared with the intensive regimens was 82% (95% CI = 66-98%). This was significantly better compared to 46% (95% CI = 19-73%; P = 0.047) in the historical group. There was a trend toward better OS (Figure 2 ) in the study group: 82% (95% CI = 65-99%) in comparison to 46% (95% CI = 19-73%; P = 0.074) in the historical group (Table 5) . Five of 13 patients in the control group relapsed 2, 3, 4, 8 and 9 months after transplantation, compared to two of 17 patients in the group treated with the more intensive preparatory regimens who relapsed at 10 and 55 months after transplantation. The 2-year relapse rate in the study group was 7% (95% CI = 0-18%). This was significantly better (P = 0.035) compared to the 45% relapse rate (95% CI = 16-74%) in the control group (Figure 3) .
Mean
Discussion
Idarubicin has been evaluated extensively in induction therapy for AML and it has been found to be superior to other anthracyclines in improving the overall survival 3, 28 and may increase the disease-free survival. 29, 30 Idarubicin also induced a higher complete remisson rate 4, 29, 31, 32 in older patients. 33 Maintenance of complete remission after remission-induction therapy for AML can be achieved by intensive consolidation therapy followed by allogeneic or autologous stem cell transplantation or by chemotherapy. 8, [12] [13] [14] Allogeneic BMT usually results in the highest disease-free survival, but its use is limited to younger patients with HLA-identical siblings. 11, 12 Autologous BMT for AML in CR1 did not improve overall survival compared to intensive consolidation therapy, mainly due to a more effective salvage therapy for those patients who relapsed after chemotherapy. However, the disease-free survival after ABMT was significantly better. [11] [12] [13] Several approaches have been attempted to intensify the antileukemic activity of conditioning regimens for allogeneic or autologous stem cell transplantation in different hematologic malignancies. Better results were not achieved by adding busulphan to cyclophosphamide and total body irradiation in advanced MDS, 34 and myeloid leukemia 35, 36 treated by allogeneic BMT. Addition of high-dose vincristine to the same conditioning regimen in children with ALL treated by allogeneic 37 or autologous 38 BMT was feasible and promising. Thiotepa, cyclophosphamide and busulphan were tolerable as conditioning for allogeneic BMT 39 and there was also a high response rate in ABMT patients 40 with hemtologic malignancies at high risk for relapse. Etoposide combined with cyclophosphamide and total body irradiation in different hematological malignancies treated with allogeneic or autologous BMT appear to offer no advantages over other regimens. [41] [42] [43] BCNU, etoposide, high-dose cyclophosphamide and fractionated TBI as conditioning for allogeneic BMT patients with advanced hematological malignancies carried a high antileukemic activity and an acceptable toxicity. 44 The addition of etoposide to cyclophosphamide and busulphan increased non-hematological skin, pulmonary and hepatic toxicity. 43, 45 Idarubicin has been administered by our team as continuous infusions in various schedules to intensify BMT conditioning regimens for allogeneic BMT. [16] [17] [18] [19] [20] 46 In these studies the data of two comparable cohorts of standard risk patients (AML CR1, ALL CR1/2, CML CP1) were compared. All patients were treated with bone marrow from histocompatible siblings followed by a short course of immunosuppression for 3-6 months. The relapse rate was significantly reduced from 52 to 26% in the idarubicintreated group. This resulted in a significantly better diseasefree survival of 56%, compared to 36% in the traditionally conditioned group. 18 The addition of anthracyclines to conditioning regimens caused more severe oromucositis and slower repopulation in the schedule when idarubicin was given as a continuous infusion until 24 h prior to the marrow infusion. 20 These side-effects and the low relapse rate may be attributed to the low concentration of idarubicin when it is given on days −12 and −11 similar to the regimens in this study, and to the presence of its cytotoxic metabolite idarubicinol at the time of autograft infusion and during the early post-transplant days.
We introduced this schedule in the autologous BMT setting since the reported relapse rate was more than 50% after conventional conditioning regimens. The 2-year diseasefree survival of 82% was significantly (P = 0.047) better than the DFS of 46% in the control group. This resulted in a trend towards (P = 0.074) better overall survival: 82% in the study group vs 46% in the historical group. This better survival was the result of a significantly (P = 0.035) reduced relapse risk: 7% in the group on the intensified regimens vs 45% in the traditionally treated group.
The differences for time to recovery, transfusion independence and for number of platelet and erythrocyte infusions were different between the two groups, although this was not statistically significant. These differences may be significant in a sample with a large number of patients. Intravenous antibiotics and antifungals were administered for longer duration in the study group. Duration of fever of more than 38.5°C was also longer in this group. The increased incidence of severe oromucositis after conditioning with idarubicin intensified regimens was substantiated by an increased usage of intravenous narcotic analgesics, and a higher usage of intravenous antibiotics and antifungal agents. The TRM was almost as high as the historical group and an increased mortality from the addition of idarubicin cannot be ruled out.
In an attempt to decrease the duration of hypoplasia and hence decrease requirement for supportive care and improve cost-effectiveness in the intensified group we recently introduced autologous peripheral blood stem cells instead of bone marrow [47] [48] [49] [50] [51] [52] as rescue. Autologous periph-eral stem cells may also decrease treatment-related mortality rate. The two groups in this analysis were not randomized. Nevertheless, the only prognostic factor which was not balanced between the two groups was the distribution of WBC above and below 30 × 19 9 /l ( Table 1) . The 2-year diseasefree survival and overall survival were not significantly different when the groups with WBC above and below 30 × 10 9 /l were compared separately in all patients and in the study group.
In conclusion, intensification of conditioning regimens with a continuous intravenous infusion of 42 mg idarubicin per m 2 over days −12 and −11 prior to marrow infusion is feasible and may result in a prolongation of DFS and OS. The low number of patients and the consecutive nature of this analysis warrants a cautious interpretation of the data. Future randomized studies with a larger number of patients are needed to confirm the promising antileukemic properties of these intensified regimens.
